On May 14, the US Centers for Disease Control (CDC) and the US Public Health Service released new clinical guidelines on using daily oral TDF/FTC (also known as Truvada) as PrEP for HIV prevention. This type of guideline is used by the US government to set national norms for health providers. It is the first such national guideline issued anywhere for PrEP use. Representatives from the CDC provided an overview of the guidelines and answer questions about their content and implications. This was followed by a moderated discussion.
Watch the full webinar here.